Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07934040 + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
PF-07934040 + gemcitabine + nab-paclitaxel is an investigational combination therapy for advanced solid tumors, particularly those harboring KRAS mutations. PF-07934040 is an oral pan-KRAS inhibitor developed by Pfizer, designed to inhibit mutant KRAS proteins that drive uncontrolled cell growth in many solid tumors. Gemcitabine is a nucleoside analog antimetabolite chemotherapy agent, and nab-paclitaxel (nanoparticle albumin-bound paclitaxel) is a microtubule inhibitor used in oncology. This combination is being tested in early-phase clinical trials, notably in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, and non-small cell lung cancer, to assess safety, tolerability, and anti-tumor activity[1][2][3][4][5][6].
- Other names
- gemcitabinenab-paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA polymerase familyKRAS (Kirsten rat sarcoma viral oncogene homolog)
Beyond the preview
Go deeper on PF-07934040 + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07934040 + gemcitabine + nab-paclitaxel.